Voyager’s Alzheimer’s Gene Therapy Cleared For Human Testing

The Tip Desk · August 6, 2026 · 3 min read

Voyager ended June with $148.8 million in liquid resources and said it expects two Alzheimer’s development milestones in the fourth quarter.

Voyager Therapeutics, Inc. (VYGR), a biotechnology company developing treatments for neurological diseases, secured U.S. regulatory clearance to begin testing its tau-silencing gene therapy in adults with early Alzheimer’s disease. The clearance advanced VY1706 beyond the preparatory steps described in its previous two quarterly updates. Voyager expects VY1706 dosing to begin and VY7523 imaging data to become available in the fourth quarter of 2026.

VY1706’s progression supplied the clearest development across those updates. In March, Voyager had targeted completion of its regulatory toxicology study in the first quarter; in May, it reported that the work was complete. The latest announcement established that the Food and Drug Administration had cleared its investigational new drug application, enabling a U.S. clinical trial. Health Canada also cleared the application for Canadian trial sites in July. Voyager expects dosing to begin in the fourth quarter, within its previously stated second-half window.

The supporting evidence remained preclinical. At the Alzheimer’s Association International Conference, Voyager presented six-month toxicology results in nonhuman primates. The company said VY1706 was well tolerated and produced sustained tau protein reductions of up to 75% in key brain regions relevant to Alzheimer’s after a single intravenous dose. Those results concerned animals; the clinical clearance marked permission to begin human testing, rather than a reported human safety or efficacy result.

The other approaching milestone involved VY7523, Voyager’s anti-tau antibody. The company expects tau positron emission tomography imaging efficacy data in the fourth quarter from its ongoing multiple ascending dose trial in participants with Alzheimer’s. Enrollment had been completed in the fourth quarter of 2025. Together, the programs represented two approaches to the same target: an antibody already undergoing clinical testing and a gene therapy moving toward its first dosing. The release supplied no new human efficacy results for either program.

A partnered gene therapy also remained on the development calendar. Voyager said Neurocrine Biosciences intends to initiate a trial of NBIB-‘223 for Friedreich’s ataxia in the second half of 2026, pending successful FDA clearance of its investigational new drug application. That condition remained separate from the clearance obtained for VY1706. The partnered program formed another prospective clinical milestone alongside Voyager’s own Alzheimer’s work.

The financial results reflected a smaller research cost base. Second-quarter research and development expenses fell to $22.0 million from $31.3 million a year earlier, primarily because of program and platform prioritization, the company said. General and administrative expenses were $7.5 million; Voyager attributed their decline primarily to restructuring actions undertaken in 2025. The quarterly net loss narrowed to $24.5 million from $33.4 million. Lower expenses accompanied that improvement even as collaboration revenue declined.

Collaboration revenue was $3.2 million, against $5.2 million in the same quarter of 2025. Voyager attributed the decrease primarily to lower revenue recognized under the Neurocrine agreement as activities moved beyond the research phase. Much of the current quarter’s reported revenue represented reimbursement for research services: $3.014 million appeared in both collaboration revenue and research expenses. Excluding those matching reimbursements, Voyager reported non-GAAP net collaboration revenue of $151,000 and net research and development expenses of $19.027 million.

Cash, cash equivalents and marketable securities stood at $148.8 million on June 30. Voyager expects those resources, together with anticipated collaboration reimbursements and interest income, to fund planned operating expenses and capital expenditures into 2028 under its current operating plans. That outlook remained conditional on both spending plans and expected inflows.

Beyond the planned first dosing, Voyager identifies early 2027 as a potential window for initial acute safety data from VY1706 and the second half of 2027 for initial biomarker-based data. Both milestones remain dependent on enrollment, the company said.